Hot Features
Premium
Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 52 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AbbVie Inc | ABBV | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 164.25 | 03:17:32 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 164.25 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 6 | 52 | - | 130.9601 - 182.89 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 03:09:21 | 1 | US$ 165.00 | USD |
AbbVie (ABBV) Options Flow Summary
AbbVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 290.14B | 1.77B | - | 54.5B | 4.86B | 2.75 | 59.66 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AbbVie News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABBV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 169.52 | 169.52 | 160.00 | 163.26 | 5,140,239 | -5.27 | -3.11% |
| 1 Month | 176.66 | 182.30 | 160.00 | 172.03 | 5,270,938 | -12.41 | -7.02% |
| 3 Months | 164.00 | 182.89 | 160.00 | 174.47 | 5,675,780 | 0.25 | 0.15% |
| 6 Months | 149.27 | 182.89 | 135.85 | 161.13 | 5,628,146 | 14.98 | 10.04% |
| 1 Year | 160.89 | 182.89 | 130.9601 | 153.27 | 5,402,207 | 3.36 | 2.09% |
| 3 Years | 108.26 | 182.89 | 105.56 | 141.81 | 6,093,074 | 55.99 | 51.72% |
| 5 Years | 78.09 | 182.89 | 62.55 | 114.60 | 7,159,631 | 86.16 | 110.33% |
AbbVie Description
| AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health. |
